FDA approves Eisai's drug Halaven for type of soft tissue cancer

January 28, 2016 8:21 PM

22 0

The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea sponge for a rare type of soft tissue cancer which has no approved treatment so far.

The drug, Halaven, was approved for use in patients who have undergone chemotherapy with drugs derived from a type of bacteria, the FDA said on Thursday. (1.usa.gov/1ZWmPRo)

Also read: U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

Read more

To category page